Corbus Pharmaceuticals (CRBP) Holdings announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes. Jefferies and Piper Sandler & Co. are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho
- Corbus Pharmaceuticals Advances CRB-701 Clinical Study for Solid Tumors
- Corbus Pharmaceuticals’ CRB-601 Study: A New Hope for Advanced Solid Tumors
- Corbus Pharmaceuticals Presents Promising CRB-701 Study Results
- Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler